Memory and effector CD8 T-cell responses after nanoparticle vaccination of melanoma patients.

Memory and effector CD8 T-cell responses after nanoparticle vaccination of melanoma patients.

Induction of cytotoxic CD8 T-cell responses is enhanced by the exclusive presentation of antigen through dendritic cells, and by innate stimuli, such as toll-like receptor ligands. On the basis of these 2 principles, we designed a vaccine against melanoma. Specifically, we linked the melanoma-specif...

Szczegółowa specyfikacja

Opis bibliograficzny
Główni autorzy:	Speiser, D, Schwarz, K, Baumgaertner, P, Manolova, V, Devevre, E, Sterry, W, Walden, P, Zippelius, A, Conzett, K, Senti, G, Voelter, V, Cerottini, J, Guggisberg, D, Willers, J, Geldhof, C, Romero, P, Kündig, T, Knuth, A, Dummer, R, Trefzer, U, Bachmann, M
Format:	Journal article
Język:	English
Wydane:	2010

Podobne zapisy

Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8⁺ T-cell responses in melanoma patients.
od: Goldinger, S, i wsp.
Wydane: (2012)

CD28-negative cytolytic effector T cells frequently express NK receptors and are present at variable proportions in circulating lymphocytes from healthy donors and melanoma patients.
od: Speiser, D, i wsp.
Wydane: (1999)

In vivo expression of natural killer cell inhibitory receptors by human melanoma-specific cytolytic T lymphocytes.
od: Speiser, D, i wsp.
Wydane: (1999)

Tetramer-guided analysis of TCR beta-chain usage reveals a large repertoire of melan-A-specific CD8+ T cells in melanoma patients.
od: Valmori, D, i wsp.
Wydane: (2000)

Analysis of the cytolytic T lymphocyte response of melanoma patients to the naturally HLA-A*0201-associated tyrosinase peptide 368-376.
od: Valmori, D, i wsp.
Wydane: (1999)

Structures of two melanoma-associated antigens suggest allosteric regulation of effector binding
od: Newman, JA, i wsp.
Wydane: (2016)

IgG-mediated down-regulation of IgE bound to mast cells: A potential novel mechanism of allergen-specific desensitization
od: Uermösi, C, i wsp.
Wydane: (2014)

IgG-mediated down-regulation of IgE bound to mast cells: a potential novel mechanism of allergen-specific desensitization.
od: Uermösi, C, i wsp.
Wydane: (2014)

Improved survival with MEK inhibition in BRAF-mutated melanoma.
od: Flaherty, K, i wsp.
Wydane: (2012)

Cytokine production by peripheral blood cells following therapy with a combined vaccine of allergen and QbG10
od: Manolova, V, i wsp.
Wydane: (2008)

Immunotherapy of melanoma.
od: Smith, C, i wsp.
Wydane: (2001)

Peripheral T cells in mice lacking p56lck do not express significant antiviral effector functions.
od: Molina, T, i wsp.
Wydane: (1993)

Intralymphatic immunotherapy: Time interval between injections is essential
od: Kündig, T, i wsp.
Wydane: (2014)

Intralymphatic immunotherapy: time interval between injections is essential.
od: Kündig, T, i wsp.
Wydane: (2014)

Immunotherapy of type-1 allergies with virus-like particles and CpG-motifs.
od: Klimek, L, i wsp.
Wydane: (2014)

Anorectal melanoma.
od: Jalleh, R.P., i wsp.
Wydane: (1988)

Novel allergen-independent immunotherapy: positive data from a phase Ila pilot study with CpG contained in virus-like particles
od: Bull, C, i wsp.
Wydane: (2007)

Integrative analysis of the melanoma transcriptome
od: Berger, Michael F., i wsp.
Wydane: (2012)

Frequent MAGE mutations in human melanoma.
od: Caballero, O, i wsp.
Wydane: (2010)

Circulating melanoma cells and survival in metastatic melanoma.
od: Rao, C, i wsp.
Wydane: (2011)

MALIGNANT-MELANOMA AND FLUORESCENT LIGHTING - REPLY
od: Beral, V, i wsp.
Wydane: (1982)

Genetic influences on the end-stage effector phase of arthritis.
od: Ji, H, i wsp.
Wydane: (2001)

Is the neutrophil the key effector cell in severe asthma?
od: Kamath, A, i wsp.
Wydane: (2005)

Malignant melanoma and bone resorption.
od: Lau, Y, i wsp.
Wydane: (2006)

Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma.
od: Kirkwood, J, i wsp.
Wydane: (2012)

Nanoparticles target distinct dendritic cell populations according to their size.
od: Manolova, V, i wsp.
Wydane: (2008)

Immune monitoring in cancer immunotherapy.
od: Romero, P, i wsp.
Wydane: (2000)

Effector Shape and Motion Optimization
od: Jiang, Rebecca H.
Wydane: (2022)

Immune effector mechanisms in malaria.
od: Marsh, K, i wsp.
Wydane: (2006)

The MITF regulatory network in melanoma
od: Chauhan, JS, i wsp.
Wydane: (2022)

The therapeutic potential of acetyl-lysine and methyl-lysine effector domains
od: Brennan, P, i wsp.
Wydane: (2012)

The therapeutic potential of acetyl-lysine and methyl-lysine effector domains
od: Brennan, P, i wsp.
Wydane: (2012)

Macrophage cytoplasmic transfer in melanoma invasion
od: Louphrasitthiphol, P, i wsp.
Wydane: (2017)

Mucosal melanoma of the upper airways tract mucosal melanoma: A systematic review with meta-analyses of treatment.
od: Jarrom, D, i wsp.
Wydane: (2016)

Lymphangiogenesis and metastasis in malignant melanoma
od: Shields, J, i wsp.
Wydane: (2003)

Resting CD4+ effector memory T cells are precursors of bystander-activated effectors: a surrogate model of rheumatoid arthritis synovial T-cell function.
od: Brennan, F, i wsp.
Wydane: (2008)

New challenges in endpoints for drug development in advanced melanoma.
od: Ribas, A, i wsp.
Wydane: (2012)

TFE3 promotes ferroptosis in melanoma
od: Dias, D, i wsp.
Wydane: (2023)

Cutting edge: distinct roles for T help and CD40/CD40 ligand in regulating differentiation of proliferation-competent memory CD8+ T cells.
od: Bachmann, M, i wsp.
Wydane: (2004)

Role of Toll-like receptors in costimulating cytotoxic T cell responses.
od: Schwarz, K, i wsp.
Wydane: (2003)